Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "L01" (1015)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
What is an ATC-Code?
ATC-Overview
Antineoplastic Agents (L01) 3 products
WHO-DDD
Page 1 of 9:
1
2
3
4
5
6
7
8
9
>>
IP
CI
Lytgobi 4 mg
21
PR
PR
k.A.
Coated tablets: Futibatinibum 4 mg
Taiho Oncology Europe
GmbH
A
FB
G
IP
CI
Lytgobi 4 mg
28
PR
PR
k.A.
Coated tablets: Futibatinibum 4 mg
Taiho Oncology Europe
GmbH
A
FB
G
IP
CI
Lytgobi 4 mg
35
PR
PR
k.A.
Coated tablets: Futibatinibum 4 mg
Taiho Oncology Europe
GmbH
A
FB
G
Bendamustine (L01AA09) 18 products
WHO-DDD
DrugBank.ca
Page 1 of 9:
1
2
3
4
5
6
7
8
9
>>
L
SIP
IP
Ribomustin 25 mg
Durchstechflasche(n)
58.04
79.20
10 %
Lyophilisate for infusion solution: Bendamustini Hydrochloridum 25 mg
CPS Cito Pharma
Services GmbH
A / SL / SO
FB
G
L
SIP
IP
Ribomustin 25 mg
5 Durchstechflasche(n)
241.17
277.35
10 %
Lyophilisate for infusion solution: Bendamustini Hydrochloridum 25 mg
CPS Cito Pharma
Services GmbH
A / SL / SO
FB
G
L
SIP
IP
Ribomustin 100 mg
Durchstechflasche(n)
187.85
219.65
10 %
Lyophilisate for infusion solution: Bendamustini Hydrochloridum 100 mg
CPS Cito Pharma
Services GmbH
A / SL / SO
FB
G
L
IP
Bendamustin Accord 25 mg
52.76
73.80
10 %
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Bendamustini Hydrochloridum 25 mg
Accord Healthcare AG
A / SL / SG
FB
G
L
IP
Bendamustin Accord 25 mg
5
219.25
254.85
10 %
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Bendamustini Hydrochloridum 25 mg
Accord Healthcare AG
A / SL / SG
FB
G
L
IP
Bendamustin Accord 100 mg
170.78
202.15
10 %
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Bendamustini Hydrochloridum 100 mg
Accord Healthcare AG
A / SL / SG
FB
G
L
IP
Bendamustin Sandoz 25 mg
52.76
73.80
10 %
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Bendamustini Hydrochloridum 25 mg
Sandoz
Pharmaceuticals AG
A / SL / SG
FB
G
L
IP
Bendamustin Sandoz 25 mg
5
219.25
254.85
10 %
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Bendamustini Hydrochloridum 25 mg
Sandoz
Pharmaceuticals AG
A / SL / SG
FB
G
L
IP
Bendamustin Sandoz 100 mg
170.78
202.15
10 %
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Bendamustini Hydrochloridum 100 mg
Sandoz
Pharmaceuticals AG
A / SL / SG
FB
G
Bendamustin Accord liquid 100
mg/4 ml
PR
PR
k.A.
Concentrate for infusion: Bendamustinum 100 mg
Accord Healthcare AG
A
FB
G
Bendamustin Accord liquid 100
mg/4 ml
5
PR
PR
k.A.
Concentrate for infusion: Bendamustinum 100 mg
Accord Healthcare AG
A
FB
G
SIP
IP
Ribomustin 25 mg
10 Durchstechflasche(n)
PR
PR
k.A.
Lyophilisate for infusion solution: Bendamustini Hydrochloridum 25 mg
CPS Cito Pharma
Services GmbH
A
FB
G
SIP
IP
Ribomustin 25 mg
20 Durchstechflasche(n)
PR
PR
k.A.
Lyophilisate for infusion solution: Bendamustini Hydrochloridum 25 mg
CPS Cito Pharma
Services GmbH
A
FB
G
SIP
IP
Ribomustin 100 mg
5 Durchstechflasche(n)
PR
PR
k.A.
Lyophilisate for infusion solution: Bendamustini Hydrochloridum 100 mg
CPS Cito Pharma
Services GmbH
A
FB
G
IP
Bendamustin Accord 100 mg
5
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Bendamustini Hydrochloridum 100 mg
Accord Healthcare AG
A
FB
G
IP
Bendamustin Sandoz 25 mg
10
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Bendamustini Hydrochloridum 25 mg
Sandoz
Pharmaceuticals AG
A
FB
G
IP
Bendamustin Sandoz 25 mg
20
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Bendamustini Hydrochloridum 25 mg
Sandoz
Pharmaceuticals AG
A
FB
G
IP
Bendamustin Sandoz 100 mg
5
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Bendamustini Hydrochloridum 100 mg
Sandoz
Pharmaceuticals AG
A
FB
G
Azacitidine (L01BC07) 12 products
WHO-DDD
DrugBank.ca
Page 1 of 9:
1
2
3
4
5
6
7
8
9
>>
L
IP
Azacitidin Stada 100 mg
218.38
253.90
10 %
Powder for injection suspension: Azacitidinum 100 mg
Spirig HealthCare AG
A / SL / SG
FB
G
L
IP
Azacitidin Stada 150 mg
304.64
347.75
10 %
Powder for injection suspension: Azacitidinum 150 mg
Spirig HealthCare AG
A / SL / SG
FB
G
L
IP
Azacitidin Viatris 100 mg
224.25
259.95
10 %
Powder for injection suspension: Azacitidinum 100 mg
Viatris Pharma GmbH
A / SL / SG
FB
G
L
SIP
IP
Vidaza 100 mg
Durchstechflasche(n)
312.78
350.75
20 %
Lyophilisat pour suspension injectable: Azacitidinum 100 mg
Bristol-Myers Squibb SA
A / SL / SO
FB
G
L
IP
Azacitidin Accord 100 mg
224.25
259.95
10 %
Powder for injection suspension: Azacitidinum 100 mg
Accord Healthcare AG
A / SL / SG
FB
G
L
IP
Azacitidin Ideogen 100 mg
189.00
223.75
10 %
Powder for injection suspension: Azacitidinum 100 mg
Ideogen AG
A / SL / SG
FB
G
L
IP
Azacitidin Sandoz 100 mg
224.25
259.95
10 %
Powder for injection suspension: Azacitidinum 100 mg
Sandoz
Pharmaceuticals AG
A / SL / SG
FB
G
L
IP
Azacitidin Spirig HC 100 mg
224.25
259.95
10 %
Powder for injection suspension: Azacitidinum 100 mg
Spirig HealthCare AG
A / SL / SG
FB
G
IP
CI
Onureg 200 mg
7
PR
PR
k.A.
Coated tablets: Azacitidinum 200 mg
Bristol-Myers Squibb SA
A
FB
G
IP
CI
Onureg 200 mg
14
PR
PR
k.A.
Coated tablets: Azacitidinum 200 mg
Bristol-Myers Squibb SA
A
FB
G
IP
Onureg 300 mg
7
PR
PR
k.A.
Coated tablets: Azacitidinum 300 mg
Bristol-Myers Squibb SA
A
FB
G
IP
Onureg 300 mg
14
PR
PR
k.A.
Coated tablets: Azacitidinum 300 mg
Bristol-Myers Squibb SA
A
FB
G
Asciminib (L01EA06) 3 products
WHO-DDD
Page 1 of 9:
1
2
3
4
5
6
7
8
9
>>
IP
Scemblix 100 mg
120
PR
PR
k.A.
Coated tablets: Asciminibum 100 mg
Novartis Pharma
Schweiz AG
A
FB
G
L
IP
CI
Scemblix 20 mg
60
1844.31
2022.20
10 %
Coated tablets: Asciminibum 20 mg
Novartis Pharma
Schweiz AG
A / SL
FB
G
L
IP
Scemblix 40 mg
60
3688.62
4028.00
10 %
Coated tablets: Asciminibum 40 mg
Novartis Pharma
Schweiz AG
A / SL
FB
G
Afatinib (L01EB03) 4 products
WHO-DDD
Page 1 of 9:
1
2
3
4
5
6
7
8
9
>>
L
IP
CI
Giotrif 20 mg
28 Tablet(s)
2116.41
2318.15
10 %
Coated tablets: Afatinibum 20 mg
Boehringer Ingelheim
(Schweiz) GmbH
A / SL
FB
G
L
IP
CI
Giotrif 30 mg
28 Tablet(s)
2116.41
2318.15
10 %
Coated tablets: Afatinibum 30 mg
Boehringer Ingelheim
(Schweiz) GmbH
A / SL
FB
G
L
IP
CI
Giotrif 40 mg
28 Tablet(s)
2116.41
2318.15
10 %
Coated tablets: Afatinibum 40 mg
Boehringer Ingelheim
(Schweiz) GmbH
A / SL
FB
G
IP
Giotrif 50 mg
28
PR
PR
k.A.
Coated tablets: Afatinibum 50 mg
Boehringer Ingelheim
(Schweiz) GmbH
A
FB
G
Alectinib (L01ED03) 1 products
WHO-DDD
Page 1 of 9:
1
2
3
4
5
6
7
8
9
>>
L
IP
CI
PP
Alecensa 150 mg
224
4344.43
4741.25
10 %
Capsules: Alectinibum 150 mg
Roche Pharma
(Schweiz) AG
A / SL
FB
G
Abemaciclib (L01EF03) 8 products
WHO-DDD
Page 1 of 9:
1
2
3
4
5
6
7
8
9
>>
L
IP
CI
Verzenios 50 mg
28
988.00
1090.95
10 %
Coated tablets: Abemaciclibum 50 mg
Eli Lilly (Suisse) SA
A / SL
FB
G
L
IP
CI
Verzenios 50 mg
56
1976.00
2165.45
10 %
Coated tablets: Abemaciclibum 50 mg
Eli Lilly (Suisse) SA
A / SL
FB
G
L
IP
CI
Verzenios 100 mg
28
988.00
1090.95
10 %
Coated tablets: Abemaciclibum 100 mg
Eli Lilly (Suisse) SA
A / SL
FB
G
L
IP
CI
Verzenios 100 mg
56
1976.00
2165.45
10 %
Coated tablets: Abemaciclibum 100 mg
Eli Lilly (Suisse) SA
A / SL
FB
G
L
IP
CI
Verzenios 150 mg
28
988.00
1090.95
10 %
Coated tablets: Abemaciclibum 150 mg
Eli Lilly (Suisse) SA
A / SL
FB
G
L
IP
CI
Verzenios 150 mg
56
1976.00
2165.45
10 %
Coated tablets: Abemaciclibum 150 mg
Eli Lilly (Suisse) SA
A / SL
FB
G
IP
CI
Verzenios 200 mg
28
1423.07
1623.85
k.A.
Coated tablets: Abemaciclibum 200 mg
Eli Lilly (Suisse) SA
A
FB
G
IP
CI
Verzenios 200 mg
56
2841.39
3158.40
k.A.
Coated tablets: Abemaciclibum 200 mg
Eli Lilly (Suisse) SA
A
FB
G
Axitinib (L01EK01) 18 products
WHO-DDD
Page 1 of 9:
1
2
3
4
5
6
7
8
9
>>
L
IP
CI
Axitinib Sandoz 1 mg
28
184.00
216.55
10 %
Coated tablets: Axitinibum 1 mg
Sandoz
Pharmaceuticals AG
A / SL / SG
FB
G
L
IP
CI
Axitinib Sandoz 1 mg
56
368.00
416.65
10 %
Coated tablets: Axitinibum 1 mg
Sandoz
Pharmaceuticals AG
A / SL / SG
FB
G
L
IP
Axitinib Sandoz 3 mg
28
552.00
616.75
10 %
Coated tablets: Axitinibum 3 mg
Sandoz
Pharmaceuticals AG
A / SL / SG
FB
G
L
IP
Axitinib Sandoz 5 mg
28
920.00
1016.95
10 %
Coated tablets: Axitinibum 5 mg
Sandoz
Pharmaceuticals AG
A / SL / SG
FB
G
L
IP
Axitinib Sandoz 5 mg
56
1840.00
2017.55
10 %
Coated tablets: Axitinibum 5 mg
Sandoz
Pharmaceuticals AG
A / SL / SG
FB
G
L
IP
Axitinib Sandoz 7 mg
28
1288.00
1417.20
10 %
Coated tablets: Axitinibum 7 mg
Sandoz
Pharmaceuticals AG
A / SL / SG
FB
G
L
IP
CI
Axitinib Spirig HC 1 mg
28
184.00
216.55
10 %
Coated tablets: Axitinibum 1 mg
Spirig HealthCare AG
A / SL / SG
FB
G
L
IP
CI
Axitinib Spirig HC 1 mg
56
368.00
416.65
10 %
Coated tablets: Axitinibum 1 mg
Spirig HealthCare AG
A / SL / SG
FB
G
L
IP
CI
Axitinib Spirig HC 3 mg
28
552.00
616.75
10 %
Coated tablets: Axitinibum 3 mg
Spirig HealthCare AG
A / SL / SG
FB
G
L
IP
CI
Axitinib Spirig HC 5 mg
28
920.00
1016.95
10 %
Coated tablets: Axitinibum 5 mg
Spirig HealthCare AG
A / SL / SG
FB
G
L
IP
CI
Axitinib Spirig HC 5 mg
56
1840.00
2017.55
10 %
Coated tablets: Axitinibum 5 mg
Spirig HealthCare AG
A / SL / SG
FB
G
L
IP
CI
Axitinib Spirig HC 7 mg
28
1288.00
1417.20
10 %
Coated tablets: Axitinibum 7 mg
Spirig HealthCare AG
A / SL / SG
FB
G
L
IP
CI
Inlyta 1 mg
28 Tablet(s)
306.67
342.40
10 %
Coated tablets: Axitinibum 1 mg
Pfizer AG
A / SL / SO
FB
G
L
IP
CI
Inlyta 1 mg
56 Tablet(s)
613.34
668.35
10 %
Coated tablets: Axitinibum 1 mg
Pfizer AG
A / SL / SO
FB
G
L
IP
CI
Inlyta 3 mg
28 Tablet(s)
920.01
994.35
10 %
Coated tablets: Axitinibum 3 mg
Pfizer AG
A / SL / SO
FB
G
L
IP
CI
Inlyta 5 mg
28 Tablet(s)
1533.35
1646.25
10 %
Coated tablets: Axitinibum 5 mg
Pfizer AG
A / SL / SO
FB
G
L
IP
CI
Inlyta 5 mg
56 Tablet(s)
3066.70
3276.10
10 %
Coated tablets: Axitinibum 5 mg
Pfizer AG
A / SL / SO
FB
G
L
IP
CI
Inlyta 7 mg
28 Tablet(s)
2146.69
2298.20
10 %
Coated tablets: Axitinibum 7 mg
Pfizer AG
A / SL / SO
FB
G
Acalabrutinib (L01EL02) 2 products
WHO-DDD
Page 1 of 9:
1
2
3
4
5
6
7
8
9
>>
L
IP
CI
Calquence 100 mg
60
4426.76
4830.80
10 %
Coated tablets: Acalabrutinibum 100 mg
AstraZeneca AG
A / SL
FB
G
IP
CI
Calquence 100 mg
60
4526.77
4939.55
k.A.
Capsules: Acalabrutinibum 100 mg
AstraZeneca AG
A
FB
G
Alpelisib (L01EM03) 6 products
WHO-DDD
Page 1 of 9:
1
2
3
4
5
6
7
8
9
>>
L
IP
CI
Piqray 150 mg
28
1483.58
1629.90
10 %
Coated tablets: Alpelisibum 150 mg
Novartis Pharma
Schweiz AG
A / SL
FB
G
L
IP
CI
Piqray 150 mg
56
2982.21
3259.75
10 %
Coated tablets: Alpelisibum 150 mg
Novartis Pharma
Schweiz AG
A / SL
FB
G
L
IP
Piqray 200 mg
28
2982.21
3259.75
10 %
Coated tablets: Alpelisibum 200 mg
Novartis Pharma
Schweiz AG
A / SL
FB
G
L
IP
Piqray 200 mg + 50 mg
14
1483.58
1629.90
10 %
Coated tablets: Alpelisibum 200 mg
Coated tablets: Alpelisibum 50 mg
Novartis Pharma
Schweiz AG
A / SL
FB
G
L
IP
Piqray 200 mg + 50 mg
28
2982.21
3259.75
10 %
Coated tablets: Alpelisibum 200 mg
Coated tablets: Alpelisibum 50 mg
Novartis Pharma
Schweiz AG
A / SL
FB
G
IP
Piqray 200 mg
14
PR
PR
k.A.
Coated tablets: Alpelisibum 200 mg
Novartis Pharma
Schweiz AG
A
FB
G
Avapritinib (L01EX18) 5 products
WHO-DDD
Page 1 of 9:
1
2
3
4
5
6
7
8
9
>>
IP
CI
Ayvakyt 25 mg
30
PR
PR
k.A.
Coated tablets: Avapritinibum 25 mg
Blueprint Medicines
(Switzerland) GmbH
A
FB
G
IP
Ayvakyt 50 mg
30
PR
PR
k.A.
Coated tablets: Avapritinibum 50 mg
Blueprint Medicines
(Switzerland) GmbH
A
FB
G
IP
Ayvakyt 100 mg
30
PR
PR
k.A.
Coated tablets: Avapritinibum 100 mg
Blueprint Medicines
(Switzerland) GmbH
A
FB
G
IP
Ayvakyt 200 mg
30
PR
PR
k.A.
Coated tablets: Avapritinibum 200 mg
Blueprint Medicines
(Switzerland) GmbH
A
FB
G
IP
Ayvakyt 300 mg
30
PR
PR
k.A.
Coated tablets: Avapritinibum 300 mg
Blueprint Medicines
(Switzerland) GmbH
A
FB
G
(L01FF10) 1 products
WHO-DDD
Page 1 of 9:
1
2
3
4
5
6
7
8
9
>>
IP
ZYNYZ 500 mg/20 ml
PR
PR
k.A.
Concentrate for infusion: Retifanlimabum 500mg / 20ml
Incyte Biosciences
International Sàrl
A
FB
G
(L01FX15) 2 products
WHO-DDD
Page 1 of 9:
1
2
3
4
5
6
7
8
9
>>
IP
Blenrep 70 mg
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Belantamabum Mafodotinum 70 mg
GlaxoSmithKline AG
A
FB
G
IP
Blenrep 100 mg
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Belantamabum Mafodotinum 100 mg
GlaxoSmithKline AG
A
FB
G
Other Antineoplastic Agents (L01X) 6 products
WHO-DDD
Page 1 of 9:
1
2
3
4
5
6
7
8
9
>>
IP
CI
Voranigo 10 mg
30
PR
PR
k.A.
Coated tablets: Vorasidenibum 10 mg
Servier (Suisse) SA
A
FB
G
IP
Voranigo 40 mg
30
PR
PR
k.A.
Coated tablets: Vorasidenibum 40 mg
Servier (Suisse) SA
A
FB
G
Nilotinib Spirig HC 50 mg
120
PR
PR
k.A.
Capsules: Nilotinibum 50 mg
Spirig HealthCare AG
A
FB
G
Nilotinib Spirig HC 150 mg
112
PR
PR
k.A.
Capsules: Nilotinibum 150 mg
Spirig HealthCare AG
A
FB
G
Nilotinib Spirig HC 200 mg
28
PR
PR
k.A.
Capsules: Nilotinibum 200 mg
Spirig HealthCare AG
A
FB
G
Nilotinib Spirig HC 200 mg
112
PR
PR
k.A.
Capsules: Nilotinibum 200 mg
Spirig HealthCare AG
A
FB
G
Aminolevulinic Acid (L01XD04) 3 products
WHO-DDD
DrugBank.ca
Page 1 of 9:
1
2
3
4
5
6
7
8
9
>>
L
IP
Ameluz 78 mg/g
2 g
193.15
226.50
10 %
Gel: Acidum Aminolaevulinicum 78 mg
Louis Widmer AG
B / SL
FB
G
L
IP
CI
Alacare 2 mg/cm2
4 plaster(s)
120.00
146.90
10 %
wirkstoffhaltiges Pflaster: Aminolaevulinatis Hydrochloridum 10.2 mg
Gebro Pharma AG
B / SL
FB
G
L
IP
CI
Alacare 2 mg/cm2
8 plaster(s)
211.20
246.10
10 %
wirkstoffhaltiges Pflaster: Aminolaevulinatis Hydrochloridum 10.2 mg
Gebro Pharma AG
B / SL
FB
G
Asparaginase (L01XX02) 1 products
WHO-DDD
DrugBank.ca
Page 1 of 9:
1
2
3
4
5
6
7
8
9
>>
IP
Enrylaze 10 mg/vial
3
PR
PR
k.A.
Injection solution: Crisantaspasum 10mg / 0.5ml
MEDA Pharmaceuticals
Switzerland GmbH
A
FB
G
Arsenic Trioxide (L01XX27) 1 products
WHO-DDD
DrugBank.ca
Page 1 of 9:
1
2
3
4
5
6
7
8
9
>>
L
IP
Trisenox 12 mg/6 ml
10
3416.68
3732.25
10 %
Concentrate for infusion: Arsenii Trioxidum 12mg / 6ml
Teva Pharma AG
A / SL
FB
G
Anagrelide (L01XX35) 4 products
WHO-DDD
DrugBank.ca
Page 1 of 9:
1
2
3
4
5
6
7
8
9
>>
IP
CI
Thromboreductin 0.5 mg
42 Capsule(s)
94.59
119.70
10 %
Capsules: Anagrelidum
OrPha Swiss GmbH
B / SL / SO
FB
G
IP
CI
Thromboreductin 0.5 mg
100 Capsule(s)
198.18
230.75
10 %
Capsules: Anagrelidum
OrPha Swiss GmbH
B / SL / SO
FB
G
IP
CI
Thromboreductin 1 mg
100 Capsule(s)
325.02
367.90
10 %
Capsules: Anagrelidum 1 mg
OrPha Swiss GmbH
B / SL / SO
FB
G
IP
CI
Xagrid 0,5 mg
100 Capsule(s)
207.67
240.45
10 %
Capsules: Anagrelidum
Takeda Pharma AG
B / SL
FB
G
Aflibercept (L01XX44) 2 products
WHO-DDD
DrugBank.ca
Page 1 of 9:
1
2
3
4
5
6
7
8
9
>>
L
IP
Zaltrap 100 mg/4 ml
Durchstechflasche(n)
388.94
439.40
10 %
concentré pour solution pour perfusion: Afliberceptum 100mg / 4ml
Sanofi-Aventis
(Suisse) SA
A / SL
FB
G
L
IP
Zaltrap 200 mg/8 ml
Durchstechflasche(n)
777.87
862.40
10 %
concentré pour solution pour perfusion: Afliberceptum 200mg / 8ml
Sanofi-Aventis
(Suisse) SA
A / SL
FB
G
(L01XX74) 1 products
WHO-DDD
Page 1 of 9:
1
2
3
4
5
6
7
8
9
>>
IP
CI
Welireg 40 mg
90
PR
PR
k.A.
Coated tablets: Belzutifanum 40 mg
MSD Merck Sharp &
Dohme AG
A
FB
G
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2025
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home
